Plain-English translation of NCT07219511 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing a new medication called in people with a specific type of heart failure called HFpEF (heart failure with preserved ejection fraction). The trial is focused on understanding whether the medication is safe, how well it's tolerated, and how it affects certain markers in the blood that relate to heart function.
HFpEF is a type of heart failure where the heart's pumping function looks normal on tests, yet patients still struggle with symptoms like shortness of breath and fatigue. Current treatments are limited, so researchers are testing this medication to see if it could offer a new treatment option.
You likely qualify if…
You likely don't qualify if…
Participants will be divided into three groups: some will receive a placebo (inactive pill), while others will receive either a lower or higher dose of . You'll attend study visits where researchers will check your heart health, take blood samples, and monitor how you're responding to the treatment. The trial is designed to be relatively short and focused on gathering safety information rather than testing whether the medication actually improves symptoms.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States